Femto Technologies Inc., a leader in the FemTech sector, has successfully secured $17 million in funding through a private placement investment. This financial boost is set to accelerate the development of the company's groundbreaking feminine wellness technologies, particularly the Sensera device, which incorporates advanced Smart Release System (SRS) technology powered by machine learning and artificial intelligence.
The investment involves the issuance of common shares and warrants to institutional investors at $4.17 per common unit, with the transaction anticipated to conclude on February 27, 2025. The Series A warrants are priced at $5.21 per common share with a 60-month expiration, while the Series B warrants are set at $12.51 per common share, expiring after 30 months. This strategic move is aimed at bolstering Femto's general corporate purposes and working capital, ensuring the continued innovation and development of its product line.
The Sensera device, recently honored with a CES Innovation Awards® 2025 designation in the AI category, exemplifies Femto's dedication to enhancing feminine wellness through technology. Designed to offer a personalized self-care experience, the device adapts to the evolving needs of women, showcasing the company's commitment to filling the gaps in feminine healthcare solutions.
Aegis Capital Corp. has been appointed as the exclusive placement agent for this private placement, which is directed solely at accredited investors. The offering is conducted privately, without a public offering, and the securities involved are not registered under the Securities Act of 1933. This significant financial achievement highlights Femto Technologies' pivotal role in the burgeoning FemTech market, promising further advancements and growth in the realm of female wellness technologies.
